Qlaris Bio is a technology company.
Qlaris Bio is a clinical stage biotechnology company focused on developing innovative first-in-class therapies for patients suffering from serious ophthalmic diseases.
Qlaris Bio has raised $24.0M across 1 funding round.
Qlaris Bio has raised $24.0M in total across 1 funding round.
Qlaris Bio has raised $24.0M in total across 1 funding round.
Qlaris Bio's investors include Adjuvant Capital, Canaan Partners.
Qlaris Bio is a clinical-stage biotechnology company focused on developing innovative, first-in-class therapies for serious ophthalmic diseases, particularly glaucoma. Its lead product, QLS-111, is a novel drug designed to lower intraocular pressure (IOP) by targeting episcleral venous pressure (EVP), a mechanism not addressed by current treatments. QLS-111 aims to serve patients with normal tension glaucoma, primary open-angle glaucoma, ocular hypertension, and rare diseases like Sturge-Weber syndrome, addressing significant unmet medical needs in eye care. The company has demonstrated promising growth momentum, advancing QLS-111 through multiple Phase II clinical trials globally, including recent expansions into markets with high prevalence of normal tension glaucoma[1][2][6].
Founded in August 2019, Qlaris Bio emerged from a collaboration that combined scientific, medical, business, and strategic expertise to tackle ophthalmic diseases with novel approaches. The company’s foundational science originated in the lab of Dr. Michael Fautsch at Mayo Clinic, where EVP was identified as a previously untreatable contributor to elevated IOP. This discovery led to the development of QLS-111, leveraging ATP-sensitive potassium channel modulation to relax vascular tissues and reduce outflow resistance. Early traction included successful preclinical validation and securing significant Series B financing to support clinical development[2][3].
Qlaris Bio is positioned at the intersection of biotechnology innovation and ophthalmology, riding the trend of precision-targeted therapies for chronic eye diseases. The timing is critical as glaucoma remains a leading cause of preventable blindness worldwide, and current treatments do not adequately address EVP. Market forces favor novel mechanisms that can improve patient outcomes and compliance, especially with an aging global population. By pioneering EVP-targeted therapy, Qlaris influences the broader ecosystem by expanding therapeutic options and encouraging further research into vascular contributions to eye diseases[1][3][5].
Looking ahead, Qlaris Bio is expected to continue advancing QLS-111 through late-stage clinical trials, potentially moving toward regulatory approval and commercialization. Trends such as increasing glaucoma prevalence and demand for safer, more effective treatments will shape its trajectory. The company’s success could validate EVP as a therapeutic target, opening avenues for additional indications and combination therapies. As Qlaris Bio matures, its influence may extend beyond glaucoma, impacting the development of treatments for other ophthalmic and vascular-related conditions, thereby fulfilling its mission to preserve vision and prevent blindness[2][6].
Qlaris Bio has raised $24.0M across 1 funding round. Most recently, it raised $24.0M Series B in April 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2024 | $24.0M Series B | Adjuvant Capital, Canaan Partners |